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Granzyme A is a serine  protease  that,  together  with 
the other  granular components of cytotoxic T lympho- 
cyte (CTL) cells, has been implicated in the cytolysis 
process. We report  here  two  different messages and 
the genomic organization of the mouse granzyme A 
gene. The  granzyme A gene is composed  of six  exons 
spanning 7 kilobases. Alternative splicing of the second 
exon  results in  the  two  transcripts.  The  two mRNA 
species encode the same mature  granzyme A protein 
but with  different  leader sequences. The  first (HFl) 
encodes a typical leader signal sequence similar to 
other granzymes, but the second (HF2) putative  leader 
sequence is different and less hydrophobic. Both mes- 
sages are present in cultured CTL cell lines and in 
normal lymphoid tissues. They are both induced when 
CTL cells are activated in vitro or in vivo. Both  mes- 
sages can be translated in uitro, although the HF1 
message appears  to be  much more efficient as a tem- 
plate.  The  putative 5’ promoter region of the HF gene 
sequenced (500 base pairs of upstream sequences) con- 
tains no  well defined promoter sequences aside  from 
the TATA  box. The  results suggest that (a) granzyme 
A may  be produced with  putative  different  leader se- 
quences from  two  different mRNAs; (6)  this may pro- 
vide  a model system for  studying alternate splicing and 
the evolution of a complex enzymatic system in  an 
organelle;  and (c )  the genomic DNA reported will be 
useful  for  studying  transcription  regulations involved 
in controlling the specific expression pattern of this 
gene. 
Cytotoxic T lymphocytes (CTLs)’ and  natural killer cells 
may have cytoplasmic granules that are exocytosed upon 
binding to  the target cells. These granules, which  have been 
implicated in the killing process, contain perforin (cytolysin) 
(1 ,2)  and at least seven serine proteases called granzymes A 
through G (3). In vivo, the mRNAs  for granzymes A and B 
are expressed in the cellular infiltrates in graft rejection (4) 
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and viral infection (5). Granzyme A, also named Hanukah 
Factor (HF, Ref. 6), BLT esterase (71, TSP-1 (81, SE-1 (9), 
and CTLA-3 (lo), is a neutral serine protease that cleaves 
after Arg or Lys residues. It also cleaves the colorimetric 
substrate benzyloxycarbonyl  ysyl thioester (BLT).  BLT 
cleavage activity has been  shown to be  released  when CTLs 
are incubated with their  target cells (11) or with specific anti- 
T cell receptor antibodies (12), or with some calcium iono- 
phore (9). 
Protease activity has long been implicated in the cell- 
mediated killing process (13-15). A potent inhibitor of BLT 
activity has been shown to  inhibit the killing ability of a CTL 
(16). More recently, a CTL cell line whose  granzyme A gene 
expression has been inhibited by an antisense gene shows 
reduced  killing potential.’ Using purified granzyme A, it has 
been shown that it can induce DNA degradation (18), a 
process associated with cell-mediated cytolysis (19). 
Many serine proteases are synthesized with an amino- 
terminal peptide of  20-30 amino acids that is  absent from the 
mature form. This leader peptide consists of a signal (pre-) 
peptide, which directs the nascent polypeptide into  the lumen 
of the rough endoplasmic reticulum, and an activation (pro-) 
peptide, which  keeps the protease in an inactive state (20). 
Granzyme A, like the  other granzymes,  does not have a leader 
peptide when it is isolated from the granules (21). It has been 
proposed that  the acidic pH of the granule environment (8) 
and/or binding to the granule proteoglycans (22) keeps it 
inactive. 
We  have  cloned the granzyme A gene and characterized its 
genomic organization. By analysis of its mRNA, we found 
that  it expresses two different granzyme A mRNAs. They 
encode the same mature protein with two different leader 
peptides. AIternative splicing of the second exon of the gran- 
zyme A gene produces the two types of mRNA.  One leader 
sequence is very similar to  that of the other granular proteins 
such as perforin and the other granzymes. The other  is differ- 
ent and less hydrophobic. Both messages are expressed in 
CTL lines and in normal lymphoid tissues, although the one 
with the typical granzyme leader sequence is much more 
abundant.  Both messages are induced in vivo or in uitro during 
activation of CTL function. 
MATERIALS AND METHODS 
Isolation of Full-length cDNAs-A subclone of the HF cDNA (6) 
lacking the poly(A) tail was used to screen 106 r e c o m b i n ~ t  bacteri- 
ophage each from the AR1 and 1E4 CTL cDNA libraries ( 6 ) .  Twenty 
positive clones were purified and  their lengths determined by restric- 
tion mapping. The two longest clones were subcloned into M13mp18 
or M13mp19 (23) for sequencing. The nucleotide sequence was deter- 
‘A. Tabnto, M. Nguyen, s. Law, J. K. Wu, M. Poe, J. T. Blake, 
M. Patel, T. J. Wu, C. Manyak, M. Silberklong, G.  Mark, M. Springer, 
N. H. Sigal, I. Weissman, C. Bleackley, E. Podack, M. Tykocinski, 
and G. C. Koo, submitted for publication. 
25488 
Genomic  Organization of the  Mouse  Granzyme A Gene 25489 
mined on both strands by the dideoxynucleotide chain termination 
method (24), and the Genepro program (Riverside Scientific) was 
used to analyze the sequence data  and calculate sequence similarities. 
Isolation of Genomic  Clones-A murine genomic library in lEMBL3 
(a kind gift of T. St. John, ICOS, Seattle, WA)  was screened with the 
HF subclone described above. The 6 X lo5 recombinant phages 
screened contained two classes of hybridizing inserts; the longest 
representative of each class was characterized further. Restriction 
mapping was done according to standard methods, and  the digested 
DNA was transferred to Genetran (Plasco). The locations of the exon 
boundaries in the HF2 cDNA (described below)  were approximated 
by comparison with the rat mast cell protease I1 gene (25), and 
restriction fragments corresponding to  the putative exons were sub- 
cloned. These fragments, used as probes on the genomic clone blots, 
gave a rough map of the genomic organization. One of the genomic 
clones had a 13-kb insert that included the entire gene and 6 kb of 
upstream sequences. The other clone had 11 kb upstream and 4 kb 
of the gene, terminating between the  third  and fourth exons. Restric- 
tion fragments covering all of the exons and 1 kb upstream of the 
first exon were subcloned into M13 for sequencing. The sequences 
were determined on both strands  as described above. 
RNA  Sources-RNA from the following cell lines was isolated in 
the presence of guanidium isothiocyanate and purified on CsCl gra- 
dients (26): AR1, an H-2d-specific CTL line derived from the C57L 
mouse strain (6); 1E4, another C57L CTL line that kills Abelson 
virus-infected H-2b targets (6); RAW112, an H-2d expressing, Abelson 
virus-induced B cell lymphoma used as  the AR1 target (6); and PC60, 
a cytolytic T cell hybridoma with inducible cytolytic activity by 
culturing for 3 days in Dulbecco's  modified Eagle's medium with 25% 
supernatant from concanavalin A-stimulated rat spleen cells (27). 
(PC60 cells  were kindly provided by  M. Nabholz, Swiss Institute for 
Experimental Research, Epliages, Switzerland). 
Primer Extension-Primer extension assay (28) was performed by 
end labeling 100 ng of an antisense oligonucleotide from the  third 
exon (E3, sequence TACGGTCTTGAGTGAGGAAC) with 50 pCi  of 
[y:P]dATP (Amersham Corp.). One-tenth of this served as the 
prlmer for cDNA synthesis on RNA from AR1 (1 pg  of poly(A)+ and 
5 pg  of total RNA), C57BL/10 spleen and lymph nodes (15 pg  of total 
RNA, kindly provided by C. Okada, Stanford University, CA), and 
RAW112 (15 pg  of total RNA). The extension products were run on 
a 6% polyacrylamide gel, and HF2 sequencing reactions based on the 
above primer were  used as size markers. 
Skin Grafts-For the allogeneic skin grafts, tail  skin pieces  (20-30 
mm') from  male C57BL/Ka mice  were grafted onto the left thorax of 
male BALB/c mice (29). Syngeneic grafts, BALB/c onto BALB/c 
and C57BL/Ka onto C57BL/Ka, and normal tail skin served as 
controls. Cells were isolated from the grafts after 8-10 days by a 
modification of the method for extracting dendritic epidermal cells 
(30). Briefly, the graft was  removed, placed in 300 pl of GNK-trypsin 
(0.1% glucose,  14.8 mM NaC1, 5.3 mM KC1 ,0.3% trypsin) and incu- 
bated at 8 "C overnight. After 16-20 h,  the epidermal layer was pulled 
away from the dermis and incubated at 37 "C in 200 pl of GNK- 
trypsin, 100 pg/ml DNase A for 15 min with gentle shaking. The 
isolated cells  were separated from the keratin debris, counted, spun 
through 10% bovine serum albumin, and frozen at -70 "C until 
analysis. Approximately 103-104 cells of assorted types were  recovered 
from each graft. 
Polymerase Chain Reaction  Analysis-Poly(A)+  RNA  was isolated 
from the skin graft-infiltrated cells and from lo6 RAW112 cells 
(negative control) according to  the method of van de Rijn et al. (31). 
The mRNA  was resuspended in 30 pl of 10 mM Tris, pH 7.5,O.l mM 
EDTA, and single-stranded cDNA  was synthesized from 10 pl. From 
tissues  and  non-CTL lines, 1 pg of total RNA  or 10 ng of poly(A)+ 
RNA was used to make cDNA; from CTL lines, one-tenth that 
amount was  used. One-third (10 pl) of the single-stranded cDNA  was 
amplified in 25 (skin graft) or 22 (purified RNA) cycles of the 
polymerase chain reaction (32). For the skin grafts, an equal amount 
of every  cDNA preparation was amplified with actin primers to ensure 
that mRNA had been recovered and  that  the cDNA synthesis  had 
worked. The number of cycles  was set by empirically determining the 
minimum amount of amplification that gave a visible HF2 band  in  a 
known positive sample. The reactions were done in  a 100-pl volume 
with cycle times and temperatures of 30 s, 94 'C; 60 s, 50 "C; 60 s, 
72 "C. The oligonucleotide primers had the following sequences: L1, 
CCATCTCTTGCTACTCTCCT (sense); L2,  CAATGGAGATTG- 
CTGCCGAT (sense); E5, TGCTACTCGGCATCTGGTTC, (anti- 
sense); actin 5' ,  CCACACCTTCTACAATGAGC (sense); and actin 
3', ATCTCCTTCTGCATCCTGTC (antisense). One-tenth of the 
PCR products was electrophoresed on a 1.5% agarose gel, transferred 
to Genetran  (Plasco), and probed with an isolated fragment corre- 
sponding to exon 4. 
In Vitro Transcription and Translation-The HF1  and HF2 cDNAs 
were cloned into pBluescript (Stratagene). The transcription and 
translation reactions were performed essentially as described (33), 
except that 14C-labeled leucine and  a  rabbit reticulocyte system (Be- 
thesda Research Laboratories) were used in the translation reaction. 
Equal amounts of RNA transcripts were used in the translation 
reactions. The translation products were examined by electrophoresis 
in a 12% polyacrylamide gel (30 acrylamide, 0.8 bisacrylamide) con- 
taining sodium dodecyl sulfate (34). A 14C-methylated protein mixture 
(Bethesda Research Laboratories) was used as  the molecular weight 
standard. After electrophoresis, the gel  was fixed, treated with 
En3Hance (Du Pont-New England Nuclear), and autoradiographed. 
Transient Expression in COS-7  Cells-The HF1  and HF2 cDNAs 
were cloned into pSRa.SD2 (kindly provided by Dan Denney, Stan- 
ford, CA). The transfection procedure was essentially as described in 
the lipofectin (Bethesda Research Laboratories) information sheet. 
Briefly, 5 pg of the appropriate DNAs were mixed with 1.5 ml of 
Optimum (Bethesda Research Laboratories) medium and  then mixed 
with 1.5 ml of the same medium containing 40  pg  of lipofectin 
(Bethesda Research Laboratories). The mixture was overlaid onto  a 
6-cm plate with COS-7 cells at 70-80% confluence. After incubation 
at 37 "C for 6 h, 3 ml  of Dulbecco's  modified Eagle's medium contain- 
ing 20% FCS was added to each plate, and  the plates were incubated 
at 37 "C for 20 more h. The medium  was then replaced with 5 ml  of 
Dulbecco's  modified  Eagle's  medium containing 10% fetal calf serum. 
At about 48 h  post-transfection, the plate was washed with phosphate- 
buffered saline twice, and  the cells were scraped into 1 ml of phos- 
phate-buffered saline and pelleted. The cell pellet was resuspended 
in 0.2 ml of phosphate-buffered saline, 0.5% Nonidet P-40 and 
incubated at 4 "C for 30 min. The cell lysate was then cleared by 
microcentrifugation at 4 "C for 15 min. One-tenth (20 pl) was used 
in a  standard BLT assay (7).  The BLTase activity was expressed as 
A405/105 cells/h. Cell extracts from COS-7 cells transfected with the 
pSRaSD2 vector alone were used to determine the background 
BLTase level. 
RESULTS 
Two Different mRNAs Encode  Granzyme A-A cDNA li- 
brary from the CTL line 1E4 was screened with the  HF clone 
(6) to find a full-length cDNA. We isolated and sequenced 
two different cDNA clones, HF1 and HF2. They  are identical 
at their 5' ends  and throughout the mature granzyme A coding 
region;  however, the HF2 clone has an  extra 126 bp inserted 
14 bp upstream of the sequence encoding the mature enzyme 
(Fig. 1A). HF1 has an open reading frame that includes a 28- 
amino acid leader peptide and the active granzyme A se- 
quence. In  the HF2 clone, this reading frame is terminated 
by a  stop codon within the insertion. It is followed  by another 
open reading frame that encodes a 25-amino acid peptide and 
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FIG. 1. Panel A, schematic representation of the two granzyme A 
cDNAs. The arrow indicates the start of the mature granzyme A 
coding region. Panel B, sequences of the granzyme leader peptides 
inferred from their cDNA sequences. The slash (/) marks the  start of 
the mature active protease. The boxes indicate matches of at least 2 
of 3 granzyme A residues; the gray indicates matches of at least four 
of all the granzyme sequences. HuHF, human granzyme A. 
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Kozak consensus sequence  (35,  36). The consensus sequence 
is cgccA/GcCAUGgc,  where the capital letters  are more con- 
served. The  HF1 initiation sequence  is AGCCACGATGAG, 
and  the HF2 initiation sequence is  ACTTGAGATGAG. The 
HF1 initiation sequence  seems to fit the consensus sequences 
better  than HF2  (see  below). 
Granzymes B-F all have conserved 20-amino acid leader 
peptides: an 18-amino  acid  hydrophobic  signal peptide and  a 
2-amino acid activation peptide (37). The leader peptide of 
the HF1 form of granzyme A is similar to  the leader peptides 
of the  other granzymes. The HF2 leader peptide, however, 
has less  sequence similarity to  the other leader peptides (Fig. 
1B). HF1,  like  granzymes  B-F, has a signal peptide that  the 
von Heijne algorithm (38) predicts will  be  cleaved to leave a 
2-amino acid activation peptide. The predicted cleavage site 
for the HF2  leader peptide is ambiguous; it could  have either 
a 2- or a 7-amino acid activation peptide. The  HF1 leader 
peptide conforms to  the  standard  structure for signal peptides 
(20). The putative HF2 signal peptide, in contrast, has its 
hydrophobic  region interrupted by a Glu and  an Asn residue. 
The HF1 sequence  is  also  more r lated to  the leader  sequence 
of human granzyme A (39) than is  HF2: the  HF1 sequence is 
46 and 69% similar to  the human sequence at  the amino acid 
and DNA levels,  respectively,  whereas the HF2  sequence is 
just 21 and 50% similar (allowing for gaps). These figures 
suggest that the HF1 form of granzyme A is the mouse 
homologue of human granzyme A, and  it probably  localizes 
to the granules with the  other granzymes and perforin. The 
HF2 form of granzyme A, however,  may  localize to different 
compartments in the cells. 
To confirm that both the  HF1  and HF2 cDNAs represent 
mRNAs  made  normally  by CTLs, we did a primer extension 
analysis on RNA from the  CTL line AR1, spleen,  lymph  node, 
and RAW112 (a  B cell  lymphoma). No specific  granzyme A 
bands are visible in the RNA from RAW112, spleen, and 
lymph nodes. The CTL line AR1, however, contains two 
specific bands (Fig.  2). The strong band (lower arrow) is the 
correct size for an HF1 transcript beginning 29 bp down- 
stream from the TATA box (see below). The  faint upper band 
(upper  arrow) is 126 bp larger, proving that  this CTL line 





FIG. 2. Primer  extension analysis using a primer (E3) from 
the third  exon. The lower arrow indicates the transcription  initia- 
tion site for the  HF1 mRNA, and  the upper arrow, the HF2 mRNA. 
Shown on the left are sequencing reactions using the  E3 primer on 
an HF2-containing plasmid. The bracket marks the region of the gel 
where a  transcript  initiating from the hypothetical second TATA box 
would appear. ARl", poly(A) RNA from AR1 cells; ARl ,  total RNA 
from AR1 cells; Spl, spleen; LN, lymph node; RA W112, a  pre-B cell 
line. 
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FIG. 3. Panel A ,  schematic representation of the PCR amplifica- 
tion strategy. The small arrows indicate the orientation and position 
of the primers relative to the mRNA. Panel B, PCR products from 
normal tissue and cell line RNAs. Each sample is shown  amplified 
with the L1, E5 primers (lanes 1 )  and the L2, E5 primers (lanes 2 ) .  
Arrows indicate the expected sizes for the products. PC-, PC60, 
uninduced; PC+, PC60, induced for three days with 25% concanavalin 
A supernatant; Liv, liver; Kid, kidney; Thy, thymus; Spl, spleen; nul 
spl, nude mouse spleen; ARl and lE4, two CTL cell lines; Raw, 
RAWl12, a  pre-B cell line. 
relative intensities of these two bands show that the HF1 
transcript is the predominant granzyme A message in AR1 
cells. Thus, both HF1 and HF2 mRNA are present in the 
CTL cell  line. 
Both Granzyme A  mRNAs Are Expressed in Normal Lymph- 
oid Tissues-Because the HF2 transcript is at low abundance 
even in CTL lines, we used the reverse transcriptase/PCR 
technique (32) to determine the pattern of HF1 and HF2 
mRNA distribution in normal lymphoid  cells. Single-stranded 
cDNA synthesized from either total or poly(A)+ RNA was 
amplified by PCR. We  used  two pairs of primers (Fig. 3A), 
one of which (Ll, E5) amplifies both the  HF1  and HF2  forms 
of the message,  giving products of  422 and 548 bp, respectively, 
and  another (L2, E5) that amplifies  only the HF2 transcripts, 
giving a 496-bp product. Fig. 3B shows the results from a 
variety of normal tissues and cell  lines. This figure  shows that 
normal lymphocytes from thymus and spleen express both 
HF1 and HF2. The spleen from a nude mouse, which has 
natural killer  cells but very few T cells,  also has both messages. 
Activated  cytolytic  cell lines (PC60, AR1, 1E4) make both 
HF1  and HF2. Both granzyme A messages are present at a 
low level in uninduced PC60 cells. Their expression is en- 
hanced concomitantly with increase of BLTase activity and 
cytotoxicity when this cell line is activated (40): 
When amplifying both HF1  and HF2 in a single reaction, 
using primers that anneal to the  first leader (Ll) and to  a 
shared downstream sequence (E5),  the amplification  condi- 
tions are identical for both messages. This allows  comparison 
of the relative abundance of the two  mRNAs  within a sample. 
Fig.  3B  shows that  the  HF1 message  is  much  more abundant 
than HF2  in all positive  samples, but it also  shows that all 
those samples do contain some HF2 message. Therefore, both 
L. Su and I. L. Weissman, unpublished results. 
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HF1 and  HF2  are expressed in  normal  lymphoid  tissues,  and 
they  are  both induced in a cell line with inducible BLTase 
and cytotoxicity activity. 
Both Granzyme A  mRNAs  Are Expressed in Lymphocytes 
from Rejecting Skin Allografts-The granzyme  A gene is in- 
duced in infiltrating lymphocytes when allogeneic heart  grafts 
are being rejected, as shown by in situ hybridization (41). 
Allogeneic skin  grafts  also evoke a CTL response  (42). There- 
fore, we set  up syngeneic and allogeneic skin  grafts  to  test 
granzyme A mRNA expression in  an in vivo immune response. 
The  skin  grafts were harvested a t  8 and  10  days  after  trans- 
plantation, lymphocytes were recovered from the  epidermal 
layer,  and  mRNA was extracted  using a method designed to 
allow  reverse transcriptase/PCR  detection of messages  from 
5103 cells (31). As shown  in Fig. 4, the  infiltrated lymphocytes 
from rejecting allografts have a high level of granzyme A 
messages. This  is  not because of an  increase  in  the  number of 
cells recovered, as shown by the reverse transcriptase/PCR 
amplification of actin  mRNA from the  same cDNA prepara- 
tions (lower panel). Therefore, both forms of granzyme A 
mRNA  are induced during a CTL  immune  response in vivo, 
although  HF1 is present at a much higher level. 
Normal C57BL/Ka  tail  skin  has  an  extremely low level of 
granzyme  A message; a faint  band  that  appears  after a  long 
exposure may be caused by the Thyl+ dendritic epidermal 
cells, which are of thymic origin (43) and  can be cytotoxic 
(44). The negative control, RAW112, never  shows any  hybrid- 
izing band.  The syngeneic  graft-derived  lymphocytes  have  a 
slight increase in granzyme A mRNA compared with the 
ungrafted  skin.  This may  reflect either  the  activation of the 
dendritic epidermal cells present in the graft or a T cell 
response to infection or  tissue  damage at   the graft  site. 
Both HFI and HF2 Can  Be Translated in  Vitro-To test 
whether  both cDNAs can produce the granzyme A protein, 
we first  tested  their  ability to produce  a protein of the expected 
size in an in vitro transcription/translation system. Both 
cDNAs  generate  protein  products of about 30 kDa (Fig. 5 A ) .  
The  HF1 mRNA appears  to be  more  efficient as a template 
for  translation because an  equal  amount of RNA was  used for 
the  translation assay. The Kozak sequences (35, 36) a t   the  
translation  initiation codon in  HF1  or  HF2  are  different  and 
may  account for the difference in  translation efficiency. 
Expression of the  HF1  and  HF2 cDNAs  was  also tested  in 
a transient expression  system. The  cDNAs were transfected 
HE> 
HFI > 
FIG. 4. PCR products  from cells recovered  from  skin grafts. 
Upper panel, three syngeneic (Syn)  grafts and four allogeneic (Allo) 
grafts are shown for each time point. The L1, E5 primer pair was 
used. Normal, normal  tail skin from C57BL/Ka mice. Lower  panel, 
ethidium  bromide-stained  agarose gel showing the  PCR amplification 
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FIG. 5. Panel A, in vitro translation of HF1  and  HF2 mRNA. The 
transcription,  translation,  and sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis were carried out  as described under “Materials 
and Methods.” The arrow indicates the  translated products. Lane 1, 
no exogenous RNA control; lane 2, translation products from HF1; 
and lane 3; from HF2. Panel B, functional expression of HF1  and 
HF2 in COS-7 cells. BLT assay of transfected cells was carried  out 
as described under  “Materials and Methods.” Each data point is from 
an average of triplicates, and each  experiment was repeated at  least 
three times. The error  bars indicate the S.D. H F l ,  cells transfected 
with pSRaSDHF1; HF2, cells transfected with pSRaSDHF2. Cell 
extracts from cells transfected  with the vector (pSRaSD2) were  used 
to determine the background. 
into COS-7 cells under  the  control of the SV40 early gene 
promoter.  Both cDNAs are  transcribed,  as shown by reverse 
transcriptase/PCR  analysis of RNA  from  the  transfected cells 
(data  not  shown).  Whole cell extracts from transfected cells 
were assayed for  BLTase  activity, which is very low in un- 
transfected COS-7 cells (data  not shown). Cells transfected 
with  the  HF1 cDNA  produce a high level of BLTase activity 
(Fig. 5B).  In  contrast,  the  BLTase  activity of cells transfected 
with  HF2  is  not significantly above background. This may be 
because of either inefficient  processing of the  HF2 granzyme 
A or inefficient translation of the  HF2 message. The leader 
sequence may also lead to a difference in protein stability. 
This  experiment shows that  functional granzyme A can be 
produced  from HF1  but  not from HF2  in  the  transient expres- 
sion  system. 
The Granzyme A Gene Has Two Separate Leader Exons- 
To examine  the origins of the two  mRNAs, we isolated two 
lEMBL3 mouse genomic clones that cover 18 kb around  the 
granzyme  A gene. The gene is composed of six  exons spanning 
7 kb (Fig. 6A). As in  many  other  serine proteases, the residues 
forming  the active site, His-41, Asp-85, and Ser-183, are all 
on  separate  exons (45). The genomic organization of granzyme 
A is  most  similar  to  that of granzymes  B and C  (46), rat  mast 
cell protease I1 (25), and adipsin (47, 48). This group is a 
subfamily of the  trypsin family of serine proteases, and  it is 
distinguished from trypsin by the position of the  third  intron 
(25, 49). However, granzyme A, unlike these other serine 
proteases,  has two different leader exons. 
We sequenced all  the exons, the  exon-intron  junctions,  and 
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FIG. 6. Panel A,  schematic r e p r e ~ n ~ t i o n  of the 18 kb encom- 
passing the granzyme A gene  and of the  mRNAs made  from it. The 
locations of the  active site residues His-41 (H), Asp-85 (D), and Ser- 
183 ( S )  are  indicated. The  restriction map i s  indicated  above  in small 
letters. e EcoRI; s, SalI; b, BamHi; h, HindIII; x, XhoI. Panel B, DNA 
sequences  of the granzyme A gene that includes 500 bp  upstream of 
the gene, all of the exons, and some of the intron sequences. The 
exon-intron boundaries are denoted by a slash. The TATA box is 
underlined, and the transcription initiation site is marked with a 
capital  letter.  The  inferred  amino  acid  sequences  are  indicated  below 
their corresponding  DNA  sequences,  and  an u ~ e r ~ i n e d  TAG marks 
the stop codon that halts transcription from the LI methionine  in 
the HF2  message. A TATA-like  sequence  in  the  first  intron is 
indicated by  italic  letters. Initrons 3,4,5 are not completely  sequenced. 
The missing length of sequences is indicated in brackets. The star 
marks the stop codon (TAA), and the polyadenylation  signal (AA- 
TAAA) is underlined. 
the region 5' of the granzyme A gene. Fig. 6B gives the 
sequences 5' of the transcription  initiation  site  and the first 
two exons, the  first  intron, the other exons and part of the 
other introns. The  first exon encodes 23 amino acids of the 
HF1 leader peptide. The second exon also encodes a partid 
leader peptide, and it is alternatively spliced if it is excluded 
the HF1 message is produced, and if it is included the  HF2 
message is made. Most of the granzyme A splice donor and 
acceptor sites conform to  the consensus sequence (Fig. 6B). 
The splice acceptor site of the second leader exon differs from 
the consensus sequence, however, in that a stretch of 5 Ala 
residues separates the polypyrimidine tract from the rest of 
the splice acceptor. Purine-rich sequences at the 3' splice 
acceptor are  present  naturally  in the introns preceding alter- 
natively spliced exons in genes from Drosophila to human 
(50). Thus,  this divergence  from the consensus splice  sequence 
may be the means for regulating the production of the two 
forms of granzyme A. 
The most common mechanism for making two different 
amino termini on a protein is the use of different transcription 
initiation sites for the mRNAs (35, 51). A TATA promoter 
element (52) lies 29 bp upstream of the transcription initiation 
site identified by primer extension analysis. In addition, there 
is a TATA-like sequence in the  first  intron (itakcized in Fig. 
6B)  that could be the promoter for an mRNA beginning with 
the second exon. However, the primer extension analysis in 
Fig. 2 shows no transcript beginning 26-34 bp downstream of 
this  site (bracket). The lack of detectable messages that begin 
with the second  exon implies that alternative splicing is the 
only mechanism that creates an mRNA encoding the second 
leader peptide for granzyme A. 
Examining the 500 bp of genomic sequences 5' of granzyme 
A (Fig. 6 B )  reveals no significant match to the consensus 
CAAT sequence, the GC box sequences, nor to the other 
consensus promoterlenhancer sequences compiled by Win- 
gender (53). Comparison with putative promoters of the other 
granzyme genes (54, 55) and the perforin gene (56) shows 
some limited matches but no significantly homologous re- 
gions. The putative regulatory sequences conserved  between 
human and mouse perforin genes (56) are  not conserved in 
the 500-bp promoter region of the mouse  granzyme A gene. 
The granzyme A gene,  whose expression is inducible and cell 
type-specific (6,57), may  provide a good system to study gene 
regulation. 
DISCUSSION 
In  an  attempt  to clone a full-length granzyme A cDNA,  two 
clones were isolated and characterized. They  share a common 
5' end and the mature protease encoding region, but the 
second  cDNA (HF2) has  an insertion of 126  bp in  the region 
encoding the putative leader peptide.  Analyses of CTL in vitro 
and immune infiltrates in vivo confirm the presence of both 
messages. They  are both induced during activation of T cells 
(presumably CTL) in vitro and in vivo, and granzyme A can 
be produced from both cDNAs in an in vitro transcription/ 
translation system. Therefore, the  HF2 cDNA appears to be 
a bona fide message expressed in cytolytic cells. 
The genomic structure of the mouse  granzyme A gene is 
similar to  other trypsin family  genes;  however, it is the only 
one in  the family that has two leader exons. Two granzyme A 
mRNAs, HF1  and HF2, are generated by alternative splicing 
of the second  exon. Analysis of the splicing junctions reveals 
that  the second  exon has a polypurine stretch adjacent to  the 
splice acceptor site. In a study on splicing of the SV40 large 
T and small t antigens, the insertion of a polypurine tract 
between the polypyrimidine tract  and  the splice acceptor had 
no  effect on the splicing efficiency, but  it  has a considerable 
effect  on the  pattern of alternative splicing (50). Therefore, 
the generation of HF2 may  be regulated by some trans-acting 
factor binding near this splice acceptor site. The granzyme A 
gene  may provide a good system to study alternative splicing, 
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as the message is very abundant  and one message is predom- 
inantly spliced over the other. 
The putative promoter region of the granzyme A gene has 
a typical TATA box 29 bp  upstream of the CAP site (Fig. 
6B). Comparison with promoter regions of genes encoding the 
CTL granular proteins perforin (56) and granzyme B (54) 
reveals no significant conserved sequence motifs. More de- 
tailed  studies of more upstream sequences are  in progress to 
characterize the regulatory elements important for its induc- 
tion in activated cytolytic cells. 
The cellular location and expression pattern of granzyme 
A imply that  it may  be  involved in  the killing process. Studies 
with protease inhibitors also indicate involvement of pro- 
teases during cell-mediated killing (13-15). Recent studies 
with purified perforin and granzyme A have shown that 
granzyme A may  be important  in inducing target cell nuclear 
and DNA degradation, an event associated with CTL-me- 
diated cytolysis (18). Specific inhibition of the granzyme A 
function in CTL cells either by an  HF antisense RNA' or by 
a  dominant negative mutant of the granzyme A gene3 indi- 
cated  that granzyme A is required for efficient killing of target 
cells. 
The granule-mediated cell lysis model has been challenged 
by the following observations. First, some in  vivo primed CTL 
do  not  contain  any cytolytic granules but  can kill target cells 
quite efficiently (59). Second, some CTL can kill target cells 
in the absence of extracellular calcium (60-62), which is 
required for granule exocytosis. Therefore, mechanisms other 
than lytic granule exocytosis have been proposed (17, 63). 
Whether these represent further redundance pathways to 
cytolysis to ensure lysis of target cells or they also use the 
granule exocytosis pathway (therefore requiring some other 
function for granule exocytosis events) is not yet clear. The 
demonstration that granzyme A can be encoded by two 
mRNAs with different leader sequences implies that  the same 
type of effector molecules  may be employed in different cel- 
lular  compartments  and/or different cytolytic pathways. It is 
conceivable that  the HF2 granzyme A may be stored  in an 
inactive form in the nongranulated  CTL cells and is activated 
during the killing processes. The HF2 message may be too 
rare  to be detected by Northern blot analysis in those cells 
(59).  The reverse transcriptase/PCR assay used in  this  study 
might be  employed to address this issue. It is also conceivable 
that HF2 message expression leads to a different function in 
the life history of cytolytic cells. For example, in uitro (18) 
study strongly supports the notion that granzyme A can 
stimulate  target cell DNA fragmentation, presumably getting 
into such target cells by perforin pores. If HF2 mRNA is 
expressed late in the life history of killer cells and results in 
release of granzyme A into  the cytosol, apoptosis-associated 
nuclear fragmentation might result. In  that view, the disap- 
pearance of cytolytic cells in  the course of an immune response 
may be triggered by a switch in  the splicing mode of HF RNA. 
Of course this speculation is only one of several possible 
explanations for the presence of HFl  and HF2 mRNA forms 
but is valuable in that  it is a  testable hypothesis. It will also 
be of interest to study if other  CTL  granular  proteins  are lso 
encoded by different mRNAs. Interestingly, a  different cDNA 
encoding human granzyme B with a different leader peptide 
has been reported recently (58). 
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